[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1940364T3 - Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser - Google Patents

Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser

Info

Publication number
DK1940364T3
DK1940364T3 DK06815221.4T DK06815221T DK1940364T3 DK 1940364 T3 DK1940364 T3 DK 1940364T3 DK 06815221 T DK06815221 T DK 06815221T DK 1940364 T3 DK1940364 T3 DK 1940364T3
Authority
DK
Denmark
Prior art keywords
pirfenidon
acceptable excipients
pharmaceutical acceptable
capsule formulation
capsule
Prior art date
Application number
DK06815221.4T
Other languages
English (en)
Other versions
DK1940364T4 (da
Inventor
Ramachandran Radhakrishnan
Ronald Vladyka
Kenneth Sultzbaugh
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1940364(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of DK1940364T3 publication Critical patent/DK1940364T3/da
Application granted granted Critical
Publication of DK1940364T4 publication Critical patent/DK1940364T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK06815221.4T 2005-09-22 2006-09-22 Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser DK1940364T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72025705P 2005-09-22 2005-09-22
PCT/US2006/037057 WO2007038315A2 (en) 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Publications (2)

Publication Number Publication Date
DK1940364T3 true DK1940364T3 (da) 2014-06-30
DK1940364T4 DK1940364T4 (da) 2022-10-24

Family

ID=37898745

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06815221.4T DK1940364T4 (da) 2005-09-22 2006-09-22 Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser

Country Status (29)

Country Link
US (5) US7988994B2 (da)
EP (2) EP1940364B2 (da)
JP (3) JP5837732B2 (da)
KR (3) KR20080046673A (da)
CN (3) CN103393607A (da)
AP (2) AP2012006231A0 (da)
AU (2) AU2006295440B2 (da)
BR (1) BRPI0616324A2 (da)
CA (2) CA2620380C (da)
CU (1) CU20080043A7 (da)
CY (1) CY1115544T1 (da)
DK (1) DK1940364T4 (da)
EA (1) EA030093B1 (da)
EC (1) ECSP088394A (da)
ES (1) ES2496144T5 (da)
GE (1) GEP20115303B (da)
HK (1) HK1117762A1 (da)
IL (2) IL189273A (da)
MA (1) MA29875B1 (da)
MX (1) MX2008003882A (da)
NO (1) NO345131B1 (da)
NZ (3) NZ591443A (da)
PL (1) PL1940364T5 (da)
PT (1) PT1940364E (da)
SI (1) SI1940364T2 (da)
TN (1) TNSN08136A1 (da)
UA (2) UA115861C2 (da)
WO (1) WO2007038315A2 (da)
ZA (1) ZA200802237B (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
MX2009006526A (es) 2006-12-18 2009-06-30 Intermune Inc Metodo para suministrar terapia con pirfenidona a un paciente.
US20080242293A1 (en) * 2007-04-02 2008-10-02 Cequint, Inc. System and method for providing caller id name display in wireless communications system
WO2008147169A2 (es) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemolsion conteniendo pirfenidona
EP2170828B1 (en) 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009111785A2 (en) * 2008-03-07 2009-09-11 Solanan, Inc. Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis
ES2567283T3 (es) * 2008-06-03 2016-04-21 Intermune, Inc. Compuestos y métodos para tratar trastornos inflamatorios y fibróticos
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
BRPI1006979A2 (pt) * 2009-01-26 2016-04-12 Intermune Inc métodos para tratar infartos agudos do miocárdio e distúrbios associados
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
CN101912395B (zh) * 2010-08-12 2012-09-26 北京凯因科技股份有限公司 一种含吡非尼酮的药物组合物及其制备方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2670242B1 (en) 2011-01-31 2022-03-16 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2828895A1 (en) 2011-03-08 2012-09-13 Auspex Pharamaceuticals, Inc. Substituted n-aryl pyridinones
CN102670632A (zh) * 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013090439A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations of guaifenesin
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
JP6522619B2 (ja) * 2013-12-13 2019-05-29 ノバルティス アーゲー 医薬剤形
CA2936330C (en) 2014-01-10 2023-01-03 Genoa Pharmaceuticals Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
US9937240B2 (en) * 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
WO2016059815A1 (ja) * 2014-10-15 2016-04-21 安良太 吾妻 癌化学予防薬
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
KR102051559B1 (ko) * 2016-12-09 2019-12-05 재단법인 아산사회복지재단 섬유증의 진단 또는 치료를 위한 스테아르산의 용도
KR20180100869A (ko) * 2017-03-02 2018-09-12 영진약품 주식회사 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
WO2018195338A1 (en) * 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3511001B1 (en) * 2018-01-12 2021-09-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Pirfenidone-containing tablet and capsule formulation
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
US20210267955A1 (en) * 2018-06-29 2021-09-02 Zenvision Pharma Llp Low dose oral pharmaceutical composition of pirfenidone or salt thereof
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
AU2020397207A1 (en) 2019-12-04 2022-07-21 Idorsia Pharmaceuticals Ltd Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230065106A1 (en) * 2020-02-06 2023-03-02 Ribomic Inc. Therapeutic agent for subretinal hyperreflective material or retinal disorders accompanying subretinal hyperreflective material
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
CN115666533B (zh) * 2020-04-22 2024-08-09 永进药品工业株式会社 具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法
CN116981683A (zh) 2021-01-25 2023-10-31 纳米智能生物医学工程有限公司 用于预防和治疗纤维化的肽
CN117224429B (zh) * 2023-11-15 2024-02-06 南京天纵易康生物科技股份有限公司 一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
DE69431433T2 (de) * 1993-05-07 2003-12-04 Solomon B. Margolin Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
US5591766A (en) * 1993-12-03 1997-01-07 Cheil Foods & Chemicals, Inc. Solid oral formulations of pyridone carboxylic acids
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
CA2232191C (en) * 1995-09-19 2011-03-15 Solomon B. Margolin Inhibition of tumor necrosis factor alpha
US20030104066A1 (en) * 2000-03-27 2003-06-05 Kouji Murai Easy-to-take granules
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
JP4280074B2 (ja) * 2001-04-25 2009-06-17 大正製薬株式会社 マルチプルユニット型徐放性錠剤
US7007089B2 (en) * 2001-06-06 2006-02-28 Akarnai Technologies, Inc. Content delivery network map generation using passive measurement data
US7512702B1 (en) * 2002-03-19 2009-03-31 Cisco Technology, Inc. Method and apparatus providing highly scalable server load balancing
US7139840B1 (en) * 2002-06-14 2006-11-21 Cisco Technology, Inc. Methods and apparatus for providing multiple server address translation
CA2496314A1 (en) 2002-08-27 2004-03-11 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
CA2496577A1 (en) 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7159034B1 (en) * 2003-03-03 2007-01-02 Novell, Inc. System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards
US20060063832A1 (en) * 2003-03-31 2006-03-23 Pliva-Lachema A.S. A Czech Republic Corporation Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
EP1633317A4 (en) 2003-05-16 2008-08-20 Intermune Inc Synthetic chemokine receptor ligands and methods of use therefor
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
JP2007527394A (ja) * 2003-07-01 2007-09-27 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 拡散層調節固体
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7825133B2 (en) 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US7584435B2 (en) * 2004-03-03 2009-09-01 Omniture, Inc. Web usage overlays for third-party web plug-in content
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients

Also Published As

Publication number Publication date
EA030093B1 (ru) 2018-06-29
JP2014169341A (ja) 2014-09-18
US7767225B2 (en) 2010-08-03
IL189273A (en) 2016-09-29
AU2006295440B2 (en) 2011-01-06
AU2006295440A1 (en) 2007-04-05
ECSP088394A (es) 2008-05-30
CA2620380C (en) 2012-10-30
JP2009509962A (ja) 2009-03-12
US20120015984A1 (en) 2012-01-19
EP1940364A2 (en) 2008-07-09
CA2762013C (en) 2014-07-08
SI1940364T1 (sl) 2014-09-30
NO20080759L (no) 2008-06-18
EP1940364B1 (en) 2014-06-11
AP2012006231A0 (en) 2012-04-30
CN103735530A (zh) 2014-04-23
ES2496144T3 (es) 2014-09-18
HK1117762A1 (en) 2009-01-23
UA115861C2 (uk) 2018-01-10
NZ565957A (en) 2012-04-27
US20130165484A1 (en) 2013-06-27
KR20130100381A (ko) 2013-09-10
EP2431025A1 (en) 2012-03-21
AP2655A (en) 2013-05-07
CN103393607A (zh) 2013-11-20
WO2007038315A2 (en) 2007-04-05
GEP20115303B (en) 2011-10-10
JP5837732B2 (ja) 2015-12-24
CA2620380A1 (en) 2007-04-05
UA99433C2 (ru) 2012-08-27
AP2008004390A0 (en) 2008-04-30
ZA200802237B (en) 2010-04-28
IL239868A0 (en) 2015-08-31
PT1940364E (pt) 2014-09-04
CU20080043A7 (es) 2011-04-26
MA29875B1 (fr) 2008-10-03
PL1940364T5 (pl) 2023-02-27
US20140242159A1 (en) 2014-08-28
NO345131B1 (no) 2020-10-12
US20090191265A1 (en) 2009-07-30
US8383150B2 (en) 2013-02-26
DK1940364T4 (da) 2022-10-24
IL189273A0 (en) 2008-06-05
ES2496144T5 (es) 2022-11-21
CN101267810A (zh) 2008-09-17
MX2008003882A (es) 2009-02-27
WO2007038315A3 (en) 2007-07-12
KR101675651B1 (ko) 2016-11-11
US7988994B2 (en) 2011-08-02
AU2011201520B2 (en) 2013-04-11
JP2012224641A (ja) 2012-11-15
TNSN08136A1 (en) 2009-07-14
JP5715101B2 (ja) 2015-05-07
NZ591443A (en) 2013-04-26
CA2762013A1 (en) 2007-04-05
KR20080046673A (ko) 2008-05-27
SI1940364T2 (sl) 2022-11-30
NZ600129A (en) 2013-12-20
EP1940364B2 (en) 2022-07-20
US8753679B2 (en) 2014-06-17
EA200800881A1 (ru) 2008-08-29
KR20140029554A (ko) 2014-03-10
KR101645069B1 (ko) 2016-08-02
US20100152250A1 (en) 2010-06-17
PL1940364T3 (pl) 2014-11-28
BRPI0616324A2 (pt) 2011-06-14
AU2011201520A1 (en) 2011-04-28
CY1115544T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
DK1940364T3 (da) Kapselformulering af pirfenidon og farmaceutisk acceptable excipienser
DK1986679T3 (da) Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
DK1753406T4 (da) Overtrukket tabletformulering og fremgangsmåde
DK1673349T3 (da) Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
DK1957110T3 (da) Fremgangsmåde til fremstilling af tygbare doseringsformer til lægemiddeladministration og produkter dermed
NO343748B1 (no) Cyklopaminanaloger og farmasøytiske preparater omfattende slike
IL184735A0 (en) Pharmaceutical formulations and methods of use
DK2294012T3 (da) Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
MA28489B1 (fr) Preparations pharmaceutiques
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
DK2049525T3 (da) N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
ATE542815T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
ATE530546T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
NO20085416L (no) Formuleringer med pulsert fenylefrinfrigivelse og farmasøytiske preparater
DK1940840T3 (da) 6-heteroarylpyridoindolon-derivater, fremstilling deraf og terapeutisk anvendelse deraf
DK2474528T3 (da) Antineoplastiske forbindelser og farmaceutiske kompositioner deraf
BRPI0810878A2 (pt) Partículas à base de polieletrólitos e de princípio ativo de liberação modificada e formulações farmacêuticas contendo estas partículas.
DK1803732T3 (da) Peptider og derivater af APL-TYPE af HSP60 og famaceutiske sammensætninger
DK1828137T3 (da) 4-Cycloalkyl-substituerede tetrahydroquinolinderivater og deres anvendelse som medikamenter
DK2106401T3 (da) Derivater af pyrrolopyridin-2-carboxamider, fremstilling deraf og terapeutisk anvendelse deraf
IS8548A (is) Úðaþurrkaðar lyfjablöndur
DK2231603T3 (da) Substituerede 3-hydroxypyridiner og farmaceutiske sammensætninger deraf
IS2204B (is) Lyfjasamsetningar af ramipríli og píretaníði